Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug

Tuesday, June 16, 2026Robert BarrieView original

SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy.

Read the full article on the original site.